By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -A boardroom shake-up at Novo Nordisk has handed ...

Sure, Eli Lilly’s Tirzepatide-based drugs have caught up significantly to Novo Nordisk’s semaglutide-based ones. As a result, ...

Get the latest on Novo Nordisk's Alzheimer's trial, stock outlook, and market risks. See what investors need to know before ...

Another week, another twist in the turnaround efforts at Novo Nordisk, the maker of the blockbuster Ozempic and Wegovy weight ...

A major boardroom shake-up at Novo Nordisk has given the Novo Nordisk Foundation an unprecedented level of control, raising ...

In a continued effort to enhance healthcare awareness and support for rare diseases, Chonburi Hospital, in collaboration with ...

The chairman of Novo Nordisk and six other independent board members quit on Tuesday after a dispute with the company’s ...

Novo Nordisk NVO and Structure Therapeutics GPCR have emerged as noteworthy companies in the obesity space. A market leader ...

"UK regulators seize illegal weight loss drugs amid global pricing shake-up" was originally created and published by ...

Semaglutide can reduce cardiac event risk regardless of a patient’s starting body fat or weight loss during treatment, ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

US-based pharma giant Eli Lilly’s blockbuster weight-loss drug, Mounjaro, is set to expand its reach across India through a ...